Cytosorbents Corp — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
CytoSorbents Corporation implemented a 20-for-1 reverse stock split, effective September 8, 2026 at 12:01 AM ET. Each 20 shares of old common stock were automatically reclassified into 1 share of new common stock, with fractional shares rounded up to whole shares. No change to stated capital, paid-in surplus, or par value ($0.001).
Why this rating
Reverse split is routine capital structure adjustment, typically non-dilutive housekeeping. No new financing, business operations, or shareholder value impacted. Common for sub-$100M companies managing stock price perception.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.